文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road.

作者信息

Hsu Robert

机构信息

Division of Medical Oncology, Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

出版信息

Transl Cancer Res. 2025 Feb 28;14(2):679-684. doi: 10.21037/tcr-24-1870. Epub 2025 Feb 26.

DOI:10.21037/tcr-24-1870
PMID:40104722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912053/
Abstract
摘要

相似文献

[1]
Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road.

Transl Cancer Res. 2025-2-28

[2]
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).

Cancer Treat Rev. 2023-7

[3]
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.

Expert Opin Biol Ther. 2023

[4]
Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer.

J Nanobiotechnology. 2025-3-6

[5]
Targeting Trop-2 in solid tumors: future prospects.

Onco Targets Ther. 2019-3-1

[6]
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Oncotarget. 2018-6-22

[7]
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.

Bosn J Basic Med Sci. 2022-2-1

[8]
[Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2024-10-20

[9]
Trop-2 expression in non-small cell lung cancer.

PLoS One. 2025-4-15

[10]
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.

Breast. 2022-12

本文引用的文献

[1]
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

J Clin Oncol. 2025-1-20

[2]
Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.

Brief Bioinform. 2024-7-25

[3]
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

J Clin Oncol. 2024-8-20

[4]
TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer.

Clin Cancer Res. 2024-2-16

[5]
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.

Lancet. 2023-10-21

[6]
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.

Expert Opin Biol Ther. 2023

[7]
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.

J Clin Oncol. 2021-8-1

[8]
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

N Engl J Med. 2021-4-22

[9]
Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.

J Mol Diagn. 2021-4

[10]
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J Clin Oncol. 2017-5-26

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索